['type 2 diabetes mellitus']
['insulin glargine (hoe901 - u300)', 'insulin glargine (hoe901 - u100)', 'background therapy']

        Inclusion criteria:

          -  Participants ≥65 years old with type 2 diabetes mellitus, inadequately controlled on
             antidiabetic regimens either including no insulin, or with basal insulin as their only
             insulin.

          -  Signed informed consent.

        Exclusion criteria:

          -  HbA1c at screening visit:

               -  <7.0% or >10.0% for participants taking basal insulin.

               -  <7.5% or >11.0% for insulin-naïve participants.

          -  History of type 2 diabetes mellitus for less than 1 year before screening.

          -  Participants not on stable basal insulin dose (±10% in the last 8 weeks prior to
             screening visit).

          -  Change in dose of antidiabetic treatment or initiation of new glucose-lowering
             medications in the last 8 weeks prior to screening.

          -  Chronic (>10 days continuous use in previous 6 months) use of bolus insulin
             injections, whether given separately or as part of a combination with basal insulin,
             e.g. premix insulin; For insulin-naïve individuals: current or previous insulin use
             except for a maximum of 10 consecutive days (e.g. acute illness, surgery) during the
             last year prior to screening.

          -  Cognitive disorder and dementia assessed clinically and by Mini-Mental State
             Examination (MMSE) score <24, or any neurologic disorder that would likely affect the
             participant's ability to follow the study procedure. The participant would be eligible
             despite an MMSE score <24 if the investigator determined that the low score reflected
             educational or cultural background and not dementia as long as the participant was
             otherwise able to meet the study requirements.

          -  Participants who had end-stage renal disease (<15 mL/min/1.73m^2, per estimated
             Glomerular filtration rate (eGFR) measurement by Modification of Diet in Renal Disease
             (MDRD).

        The above information was not intended to contain all considerations relevant to a
        participant's potential participation in a clinical trial.
      